Substack ~ Dr. Robert Malone - May 21, 2022 (introduction)

Monkeypox was first identified in 1958 in colonies of monkeys, and the first human case of the virus was identified in 1970 in the Democratic Republic of the Congo. Most likely this was just the first case identified, as people living in Africa have been in contact with monkeys and the other Monkeypox animal hosts for millennia. The “West African” monkeypox clade (clade = variant) circulating outside of Africa at this time causes a milder disease compared to the closely related virus found found in other regions of Africa (Congo clade).

The symptoms of monkeypox are somewhat similar to, but much milder than smallpox disease. The general clinical presentation of the disease caused by the West African monkey pox clade virus involves Influenza-like symptoms — fever, body aches, chills — together with swollen lymph nodes. A rash on the palm of the hand is often observed. In the latter stage of the disease, which may last for up to a month or more in some cases, may involve small lesions which develop a crust, and which can result in a small depigmented scar. There is no evidence of asymptomatic transmission.

In other words, current medical knowledge indicates that it is only spread by person to person contact between an uninfected individual and someone who already has symptoms of the disease. Therefore, disease spread can be readily controlled by classical public health interventions such as contact tracing, temporary quarantine of those who have had physical contact with someone who is infected, and longer term quarantine of those who develop symptoms. Essentially all of the current cases in the west which we are seeing in the news are among men who have sex with men, and appear to be due to close physical contact. Monkeypox is endemic in many parts of Africa, and is a “zoonotic” virus, meaning it can be transmitted from a variety of animals (not just monkeys) to humans.

Initial animal to human transmission followed by limited human to human transmission is probably the cause of the sporadic cases typically observed in Africa. Chicken pox, which is highly transmissible, is not part of the genus Orthopoxvirus, despite that name “pox.” Once again for emphasis, Cowpox and Camelpox are also in the genus Orthopoxvirus, and they are not particularly pathogenic when contracted by humans; just because Monkeypox is a “pox” virus in the genus Orthopoxvirus, does not mean it is particularly deadly.

Monkeypox is a double stranded DNA virus, which means that due to the double stranded nature of DNA each of the two strands act as a “check” on the other during replication. As a consequence of this “error checking”, this and other DNA viruses mutate much more slowly than RNA viruses do. Over time, DNA virus genomes are relatively stable. This means that, unlike SARS-CoV-2 (COVID) or influenza, Monkeypox is unlikely to rapidly evolve to escape either naturally acquired or vaccine induced immunity.

For the purposes of making a vaccine, this makes it a much easier target that say, a rapidly evolving RNA Coronavirus such as SARS-CoV-2, the virus which causes COVID-19. Furthermore, from an immunological point of view, the various Orthopox viruses often are cross-protective. In other words, if you have been vaccinated with a smallpox vaccine, or previously infected by Cowpox, Camelpox, or Monkeypox, you are highly likely to be quite resistant to disease caused by the Monkeypox virus which is now being (quite rarely) reported in non-African countries.

Current data indicate that Monkeypox is not very infectious in humans - it has a low Ro (perhaps below 1), which is the term used to describe how efficiency an infectious disease can spread from human to human. Again, this is super good news for containment. An Ro of <1 generally means that (even in the absence of social distancing of other containment measures), for every person already infected, on average less than one other person will become infected.

For comparison purposes, the Omicron variants of SARS-CoV-2 have an Ro in the range of 7 to 10. A virus with an Ro of less than one can be easily contained with the standard public health methods discussed above. A virus with an Ro of 7-10 essentially cannot be contained and will rapidly spread throughout the world, as we have seen with the Omicron variants. In the case of a virus with an Ro around 1 or less, traditional infectious disease containment methods such as contact tracing, identification and isolation of infected individuals can be all that is needed to control the virus.

Now the fact that Monkeypox is being spread from human to human (rather than only arising from contact between a person and an infected animal) is not such good news, but since this transmission appears to be from very close contact, this means that it can be easily contained without resorting to a general population vaccination campaign. In this type of setting, if there is a significant outbreak, vaccination is often restricted to just the health care and/or first responder personnel most likely to be in contact with an infected person. Using a vaccine to help that containment via either “ring” vaccination or wide-spread vaccination strategies is generally unnecessary, and may even be counterproductive, depending on the safety of the vaccine - keeping in mind that no drug or vaccine is perfectly safe.

Let me take a moment to tell a personal story to illustrate this point. After the 9-11 events including the anthrax letters, I took a job involving clinical development of a wide range of biodefense vaccines under a US Department of Defense (DoD) contract (issued to Dynport Vaccine Company). One of the vaccine indications we worked on was for prevention of Smallpox. The Vice President of the United States at the time, Mr. Dick Cheney, was advocating for widespread vaccination against smallpox because it was thought that there was something like a 1% chance of a bioterror attack involving reintroduction of smallpox into the United States. more ¹⁾

Unlimited Hangout by Whitney Webb - May 20, 2022

Two corrupt companies were in rocky financial territory just a few weeks ago. Now, with concerns over a global monkeypox outbreak being hyped by media and global health organizations alike, the worries – and sins – of these two firms are quickly being forgotten.

In recent days, concern over a global outbreak of monkeypox, a mild disease related to smallpox and chickenpox, has been hyped in the media and health ministries around the world, even prompting an emergency meeting at the World Health Organization (WHO). For some, fears have centered around monkeypox being the potential “next pandemic” after Covid-19. For others, the fear is that monkeypox will be used as the latest excuse to further advance draconian biosecurity policies and global power grabs.

Regardless of how the monkeypox situation plays out, two companies are already cashing in. As concern over monkeypox has risen, so too have the shares of Emergent Biosolutions and SIGA Technologies. Both companies essentially have monopolies in the US market, and other markets as well, on smallpox vaccines and treatments. Their main smallpox-focused products are, conveniently, also used to protect against or treat monkeypox as well. As a result, the shares of Emergent Biosolutions climbed 12% on Thursday, while those of SIGA soared 17.1%.

For these companies, the monkeypox fears are a godsend, specifically for SIGA, which produces a smallpox treatment, known by its brand name TPOXX. It is SIGA’s only product. While some outlets have noted that the rise in the valuation of SIGA Technologies has coincided with recent concerns about monkeypox, essentially no attention has been given to the fact that the company is apparently the only piece of a powerful billionaire’s empire that isn’t currently crumbling.

That billionaire, “corporate raider” Ron Perelman, has deep and controversial ties to the Clinton family and the Democratic party as well as troubling ties to Jeffery Epstein. Aside from his controlling stake in SIGA, Perelman has recently made headlines for rapidly liquidating many of his assets in a desperate bid for cash.

Similarly, Emergent Biosolutions has also been in hot water. The company, which has troubling ties to the 2001 Anthrax attacks, came under fire just under two weeks ago for engaging in a “cover up” over quality control issues relating to their production of Covid-19 vaccines. A Congressional investigation found that quality control concerns at an Emergent-run facility led to more than 400 million doses of Covid-19 vaccines being discarded. The Emergent factory in question had been shut down by the FDA in April 2021. They were allowed to reopen last August before the government terminated the contract. Given that the majority of the company’s business is tied to US government contracts, the loss of this contract, and the accompanying poor publicity, the news that its smallpox vaccine may soon be of international interest is likely seen as a godsend by the company.

Notably, this the second time in a year that both companies have benefitted from pandemic or bioterror fears propagated by the media. Last November, speculation rose that a re-emergence of the eradicated virus that causes smallpox would soon take place. This first began with Bill Gates’ comments on the prospects of smallpox bioterrorism during a November 4th, 2021 interview and was followed by the November 16th announcement of a CDC/FBI investigation into 15 suspicious vials labeled “smallpox” at a Merck facility in Philadelphia. Now, roughly six months later, the same fears are again paying off for the same two companies.

Emergent Biosolution was previously known as BioPort. The company was founded by Fuad el-Hibri, a Lebanese businessman, who leveraged his contacts with powerful US former military officials and politicians, to take control of a flailing Michigan factory. It was the only factory authorized to produce an anthrax vaccine.

The anthrax vaccine was known to have major problems even before BioPort had acquired it, and is believed by many investigators to be one of the main causes of “Gulf War” syndrome. The vaccine itself, originally developed at Fort Detrick, had little to no safety track record at the time it was administered to US troops in the First Gulf War – a problem that was never remedied. However, its chronic safety issues and its clumsy, multi-dose regimen would later prompt BioPort/Emergent Biosolutions to spend years developing a new formulation of its anthrax vaccine.

The creation of BioPort coincided with the Clinton administration’s efforts to mandate the anthrax vaccine for all members of the US Armed Forces. With control over the only source of anthrax vaccine, BioPort was poised to make a killing.(more)

Other assets held by Perelman’s company MacAndrews & Forbes are also drowning in debt. One of the few assets of the company that isn’t currently haemorrhaging money or struggling with debt is its shares in SIGA Technologies. Perelman’s main company, MacAndrews & Forbes, has long been one of SIGA’s biggest investors and remains its largest shareholder, controlling 33% of all shares.

Since Perelman got involved with SIGA, accusations of corruption have plagued the company. For instance, in May 2011, SIGA was given a no-bid contract worth about $433 million to develop and produce 1.7 million doses of anti-viral drug for smallpox. At the time there was no evidence the smallpox drug in question was capable of treating the disease and there was alarm among some HHS staffers that SIGA’s return on investment from the contract was “outrageous.” The contract began to be investigated over concerns that the contract had been awarded to SIGA precisely because it was controlled by Perelman, who had donated heavily to Barack Obama. ²⁾